AI Summary Sovaldi (sofosbuvir) is a nucleotide polymerase inhibitor used as a backbone of combination direct-acting antiviral regimens for chronic hepatitis C, typically dosed at 400 mg once daily for 8 to 24 weeks.
Medically reviewed.
Sovaldi (sofosbuvir) is a prescription antiviral medication used to treat chronic hepatitis C virus (HCV) infection. It belongs to a class of drugs called nucleotide polymerase inhibitors, which block the enzyme HCV needs to copy itself. Sovaldi is not used alone — it forms the backbone of combination direct-acting antiviral (DAA) regimens, paired with other antivirals to help most patients reach a hepatitis C cure. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Sovaldi's role in HCV treatment — how it works, who may be eligible, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether Sovaldi-based therapy fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT SOVALDI TREATMENT
Sovaldi is a prescription antiviral medicine, and its generic name is sofosbuvir. It belongs to a class of medications called nucleotide polymerase inhibitors, which block an enzyme the hepatitis C virus (HCV) needs to copy itself.
Sovaldi is not prescribed as a stand-alone medication. It is always used in combination with other direct-acting antiviral (DAA) agents, forming the backbone of many hepatitis C treatment regimens — including combination pills such as Harvoni (ledipasvir/sofosbuvir).
By blocking the HCV NS5B RNA-dependent RNA polymerase enzyme, Sovaldi helps reduce the amount of hepatitis C virus in the bloodstream. This is an interferon-free approach to treatment, and for many patients, Sovaldi-based combination therapy can help achieve sustained virologic response (SVR) — considered a cure for hepatitis C. Treatment is typically paired with regular monitoring, such as HCV RNA levels and Liver Function Tests (LFTs).
WHO SOVALDI MAY BE SUITABLE FOR
Eligibility for Sovaldi-based therapy depends on your HCV diagnosis, genotype, treatment history, and overall liver health. Your healthcare provider may consider Sovaldi if you have chronic hepatitis C requiring combination antiviral therapy, have an HCV genotype where sofosbuvir-based therapy is indicated, need an interferon-free treatment option, or need a backbone agent to pair with other DAAs.
Because Sovaldi is always used in combination with other antivirals, your provider will select a specific regimen and treatment length based on your HCV genotype, whether you have been treated for hepatitis C before, and whether you have cirrhosis or other liver disease.
Because every patient's health profile is different, there is no one-size-fits-all answer to who should take Sovaldi. Treatment decisions are individualized and should be made by a qualified healthcare professional after reviewing your HCV genotype, treatment history, and liver condition.
ELIGIBILITY OVERVIEW
Sovaldi-based combination therapy may be considered for adults with the following conditions or treatment goals:
Before recommending a Sovaldi-based regimen, healthcare providers evaluate several factors to determine the right combination and treatment length, including:
HOW SOVALDI CAN HELP YOUR LIVER
Sovaldi inhibits the HCV NS5B RNA-dependent RNA polymerase, an enzyme the hepatitis C virus needs to copy its genetic material. By blocking this enzyme, Sovaldi stops the virus from replicating.
As viral replication slows, the amount of hepatitis C virus in the bloodstream (viral load) drops. Sovaldi is always paired with at least one other direct-acting antiviral (DAA) that targets a different step of the HCV life cycle, so together they attack the virus from multiple angles.
For most patients, this combination approach helps achieve sustained virologic response (SVR) — undetectable HCV RNA maintained after finishing treatment, which is considered a cure for hepatitis C. Sovaldi-based therapy is interferon-free, and treatment response is tracked with regular HCV RNA testing and Liver Function Tests (LFTs).
LIVER BENEFITS
Sovaldi inhibits the HCV NS5B RNA polymerase, directly blocking the virus from copying its RNA and reproducing.
As replication slows, the amount of hepatitis C virus circulating in the bloodstream decreases.
Sovaldi is paired with other direct-acting antivirals that target different steps of the HCV life cycle, increasing the chance of a lasting cure.
For many patients, Sovaldi-based combination therapy helps achieve sustained virologic response (SVR), meaning the virus is no longer detectable in the blood after treatment ends.
Sovaldi blocks the enzyme hepatitis C needs to replicate, and as part of combination therapy it helps most patients reach a lasting cure. It should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
Sovaldi is supplied as an oral tablet. Take it exactly as prescribed by your healthcare provider, and check with your pharmacist if you have any questions.
The usual dose is 400 mg once daily. Sovaldi is always used in combination with other direct-acting antiviral agents — never on its own. Your healthcare provider selects the specific combination for you.
Take Sovaldi once daily with or without food, at the same time each day. Always use it exactly as your healthcare provider directs, and do not adjust your dose without medical guidance.
Sovaldi-based therapy is a time-limited, cure-oriented course — typically 8 to 24 weeks, depending on the specific regimen, HCV genotype, prior treatment history, and presence of liver disease. Complete the full course even if you feel well.
Store Sovaldi tablets at room temperature, away from moisture and heat.
Your healthcare provider will regularly monitor HCV RNA levels and liver function tests to track how well the virus is responding to treatment. Report any side effects or unusual symptoms to your healthcare provider.
BENEFITS AND SAFETY
Sovaldi-based combination therapy is a cornerstone of modern hepatitis C treatment. By blocking the enzyme HCV needs to replicate and pairing Sovaldi with other direct-acting antivirals, most patients reach sustained virologic response (SVR) — an undetectable viral load that is considered a cure. This is an interferon-free approach, and the specific regimen and length of treatment depend on HCV genotype, prior treatment history, and presence of liver disease. Sovaldi is not used on its own — it works as a backbone paired with other antivirals as part of a complete treatment plan supervised by your healthcare provider.
As with any medication, Sovaldi can cause side effects. Common ones are generally mild, such as fatigue, headache, nausea, and insomnia. If used together with ribavirin, anemia may also occur. Your healthcare provider will monitor your response and side effects with regular blood tests, including HCV RNA levels and liver function tests, and can adjust your treatment plan if needed.
BENEFITS
Sovaldi-based combination therapy helps most patients achieve sustained virologic response (SVR), which is considered a cure for hepatitis C.
Sovaldi forms the backbone of several DAA regimens, working alongside other antivirals to achieve high cure rates.
Sovaldi is a once-daily oral tablet, offering a simple regimen without injections.
Sovaldi provides strong suppression of HCV replication, helping reduce viral load quickly during treatment.
Most side effects are mild. Your healthcare provider will discuss the potential benefits and risks before treatment and monitor you with regular blood tests, including HCV RNA and liver function tests, to ensure safe use.
Sovaldi-based therapy works best alongside liver-protective lifestyle measures such as avoiding alcohol, maintaining a balanced diet, staying hydrated, and managing other conditions that affect liver health.
After you reach sustained virologic response (SVR), or cure, protecting your liver and avoiding reinfection risk behaviors remain important parts of your long-term liver health.
Areas that may support treatment:
COMMON QUESTIONS
No, Sovaldi (sofosbuvir) is never prescribed as a stand-alone medication. It always works as part of a combination direct-acting antiviral (DAA) regimen, paired with at least one other antiviral that targets a different step of the hepatitis C virus's life cycle. This combination approach is what allows most patients to reach a lasting cure. Your healthcare provider will select the specific combination and length of treatment based on your HCV genotype, treatment history, and liver health. Always discuss your treatment plan with a qualified healthcare professional before starting therapy.
Candidates for Sovaldi-based therapy are adults with chronic hepatitis C whose HCV genotype responds to sofosbuvir-containing regimens. Your provider will also consider your treatment history, whether you have cirrhosis or other liver disease, kidney function, and any other medications you take before recommending a specific combination. Because eligibility depends on several individual factors, there is no single answer that applies to everyone. A healthcare professional can review your HCV genotype and overall liver health to determine whether Sovaldi-based therapy is right for you.
Sovaldi-based combination therapy helps most patients reach sustained virologic response (SVR), meaning the hepatitis C virus becomes undetectable in the blood after treatment ends — considered a cure. Sovaldi blocks the HCV NS5B polymerase enzyme the virus needs to replicate, and pairing it with other direct-acting antivirals attacks the virus from multiple angles. Effectiveness depends on factors like HCV genotype, prior treatment, and liver condition. Your healthcare provider will confirm your results with HCV RNA testing and can discuss what outcome to expect for your specific case.
The most commonly reported side effects of Sovaldi are fatigue, headache, nausea, and insomnia, and these are usually mild. If Sovaldi is combined with ribavirin, anemia can also occur. Most side effects resolve as treatment continues or after the course ends. Your healthcare provider will monitor you with regular blood tests, including HCV RNA levels and liver function tests, throughout treatment. Report any side effects or symptoms that concern you to your healthcare provider, who can adjust your care plan if needed.
Sovaldi-based treatment typically lasts 8 to 24 weeks, depending on the specific combination regimen prescribed. Your healthcare provider determines the exact duration based on your HCV genotype, whether you have been treated for hepatitis C before, and whether you have cirrhosis or other liver disease. It's important to complete the full course as prescribed, even if you start feeling well, since stopping early can affect your chances of reaching a cure. Discuss any questions about your treatment timeline with your healthcare professional.
Sovaldi requires caution in people with significant kidney impairment, and your healthcare provider will check kidney function before starting treatment. Because some sofosbuvir-based regimens need dose or monitoring adjustments for reduced kidney function, this is one of the factors your provider evaluates alongside your HCV genotype, liver condition, and other medications. Never start or adjust Sovaldi-based therapy without medical guidance. A healthcare professional can review your kidney function and full medical history to determine whether this treatment is appropriate for you.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
